The Filing Desk

Janux Therapeutics vs Roivant Sciences

Janux Therapeutics JANX · Roivant Sciences ROIV · Biotechnology

Janux Therapeutics reported revenue of $10 million in fiscal 2025, 1.2 times Roivant Sciences' $8 million in fiscal 2025. Janux Therapeutics' revenue fell 5.5% in its latest year, and Roivant Sciences' fell 71.6%. Janux Therapeutics had an operating margin of -1576.7%, against -6235.7% at Roivant Sciences. Free cash flow was −$83 million at Janux Therapeutics and −$759 million at Roivant Sciences. Their fiscal years end in different months (December 31 and March 31), so the periods don't line up exactly.

Side by side

Janux TherapeuticsRoivant Sciences
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Mar 31, 2026
Revenue$10M$8M
Revenue growth−5.5%−71.6%
Revenue growth a year, last 5 years—−19.0%
Gross margin——
Operating margin−1,576.7%−6,235.7%
Net margin−1,136.2%−3,629.2%
Free cash flow−$83M−$759M
Free cash flow margin−832.8%−9,183.5%
Return on capital—−62.6%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count15.3%−4.3%
Last close$11.37$39.53
P/E at the last close——
Insider trades, last 12 months—sold $607.1 million
Piotroski F-score—1 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Janux TherapeuticsRoivant Sciences
Operating margin
Percent of revenue
Janux TherapeuticsRoivant Sciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Janux TherapeuticsRoivant Sciences

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Janux Therapeutics and Roivant Sciences pages.